Viking Therapeutics (LTS:0VQA) EBITDA Margin %: 0.00% (As of Mar. 2026)


LTS:0VQA Viking Therapeutics Inc LTS:0VQA
29 GF Score
Price $38.19
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics EBITDA Margin %?

Viking Therapeutics LTS:0VQA +1.18% 29 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates LTS:0VQA with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 942 Biotechnology companies, Viking Therapeutics ranks worse than 106157.01% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Viking Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-164.04 Mil. Viking Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Viking Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Viking Therapeutics  (LTS:0VQA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Viking Therapeutics EBITDA Margin % Related Terms

Viking Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Viking Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viking Therapeutics EBITDA Margin % Chart

Viking Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Viking Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0VQA vs EWTX, ACAD, DNLI: EBITDA Margin % Comparison

For the Biotechnology subindustry, Viking Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viking Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's EBITDA Margin % falls into.


LTS:0VQA
29GF Score
Viking Therapeutics Inc LTS:0VQA
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viking Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Viking Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-392.911/0
= %

Viking Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-164.04/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Viking Therapeutics (LTS:0VQA) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Viking Therapeutics and its competitors. According to the industry distribution chart, Viking Therapeutics ranks #999999 out of 942 companies in the Biotechnology industry.
Is Viking Therapeutics' EBITDA Margin % too high?
Viking Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Viking Therapeutics ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Viking Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' EBITDA Margin % compare to EWTX and ACAD?
According to the Biotechnology industry distribution chart, Viking Therapeutics ranks #999999 out of 942 companies for EBITDA Margin %. This places Viking Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Viking Therapeutics and its competitors. Viking Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (LTS:0VQA) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Viking Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Viking Therapeutics (LTS:0VQA), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viking Therapeutics Business Description

Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
29GF Score

Get the complete analysis for LTS:0VQA

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.19
Price